Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

The forefront of ovarian cancer therapy: update on PARP inhibitors

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

Mirza, MR, Coleman, RL, González-Martín, A, Moore, KN, Colombo, N, Ray-Coquard, I & Pignata, S 2020, 'The forefront of ovarian cancer therapy: update on PARP inhibitors', Annals of Oncology, bind 31, nr. 9, s. 1148-1159. https://doi.org/10.1016/j.annonc.2020.06.004

APA

Mirza, M. R., Coleman, R. L., González-Martín, A., Moore, K. N., Colombo, N., Ray-Coquard, I., & Pignata, S. (2020). The forefront of ovarian cancer therapy: update on PARP inhibitors. Annals of Oncology, 31(9), 1148-1159. https://doi.org/10.1016/j.annonc.2020.06.004

CBE

Mirza MR, Coleman RL, González-Martín A, Moore KN, Colombo N, Ray-Coquard I, Pignata S. 2020. The forefront of ovarian cancer therapy: update on PARP inhibitors. Annals of Oncology. 31(9):1148-1159. https://doi.org/10.1016/j.annonc.2020.06.004

MLA

Vancouver

Mirza MR, Coleman RL, González-Martín A, Moore KN, Colombo N, Ray-Coquard I o.a. The forefront of ovarian cancer therapy: update on PARP inhibitors. Annals of Oncology. 2020 sep;31(9):1148-1159. https://doi.org/10.1016/j.annonc.2020.06.004

Author

Mirza, M R ; Coleman, R L ; González-Martín, A ; Moore, K N ; Colombo, N ; Ray-Coquard, I ; Pignata, S. / The forefront of ovarian cancer therapy : update on PARP inhibitors. I: Annals of Oncology. 2020 ; Bind 31, Nr. 9. s. 1148-1159.

Bibtex

@article{29fb15b4585a472e83c8c4643f340e8e,
title = "The forefront of ovarian cancer therapy: update on PARP inhibitors",
abstract = "BACKGROUND: In recurrent ovarian cancer, poly(ADP-ribose) polymerase (PARP)-inhibiting agents have transformed the treatment of platinum-sensitive disease. New data support use of PARP inhibitors earlier in the treatment algorithm.DESIGN: We review results from recent phase III trials evaluating PARP inhibitors as treatment and/or maintenance therapy for patients with newly diagnosed ovarian cancer. We discuss the efficacy and safety of these agents in the all-comer and biomarker-selected populations studied in clinical trials, and compare the strengths and limitations of the various trial designs. We also consider priorities for future research, with a particular focus on patient selection and future regimens for populations with high unmet need.RESULTS: Four phase III trials (SOLO-1, PAOLA-1/ENGOT-OV25, PRIMA/ENGOT-OV26 and VELIA/GOG-3005) demonstrated remarkable improvements in progression-free survival with PARP inhibitor therapy (olaparib, niraparib or veliparib) for newly diagnosed ovarian cancer. Differences in trial design (treatment and/or maintenance setting; single agent or combination; bevacizumab or no bevacizumab), patient selection (surgical outcome, biomarker eligibility, prognosis) and primary analysis population (intention-to-treat, BRCA mutated or homologous recombination deficiency positive) affect the conclusions that can be drawn from these trials. Overall survival data are pending and there is limited experience regarding long-term safety.CONCLUSIONS: PARP inhibitors play a pivotal role in the management of newly diagnosed ovarian cancer, which will affect subsequent treatment choices. Refinement of testing for patient selection and identification of regimens to treat populations that appear to benefit less from PARP inhibitors are a priority.",
keywords = "niraparib, olaparib, ovarian cancer, PARP inhibitor, phase III, veliparib",
author = "Mirza, {M R} and Coleman, {R L} and A Gonz{\'a}lez-Mart{\'i}n and Moore, {K N} and N Colombo and I Ray-Coquard and S Pignata",
note = "Copyright {\textcopyright} 2020 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved.",
year = "2020",
month = sep,
doi = "10.1016/j.annonc.2020.06.004",
language = "English",
volume = "31",
pages = "1148--1159",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "9",

}

RIS

TY - JOUR

T1 - The forefront of ovarian cancer therapy

T2 - update on PARP inhibitors

AU - Mirza, M R

AU - Coleman, R L

AU - González-Martín, A

AU - Moore, K N

AU - Colombo, N

AU - Ray-Coquard, I

AU - Pignata, S

N1 - Copyright © 2020 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved.

PY - 2020/9

Y1 - 2020/9

N2 - BACKGROUND: In recurrent ovarian cancer, poly(ADP-ribose) polymerase (PARP)-inhibiting agents have transformed the treatment of platinum-sensitive disease. New data support use of PARP inhibitors earlier in the treatment algorithm.DESIGN: We review results from recent phase III trials evaluating PARP inhibitors as treatment and/or maintenance therapy for patients with newly diagnosed ovarian cancer. We discuss the efficacy and safety of these agents in the all-comer and biomarker-selected populations studied in clinical trials, and compare the strengths and limitations of the various trial designs. We also consider priorities for future research, with a particular focus on patient selection and future regimens for populations with high unmet need.RESULTS: Four phase III trials (SOLO-1, PAOLA-1/ENGOT-OV25, PRIMA/ENGOT-OV26 and VELIA/GOG-3005) demonstrated remarkable improvements in progression-free survival with PARP inhibitor therapy (olaparib, niraparib or veliparib) for newly diagnosed ovarian cancer. Differences in trial design (treatment and/or maintenance setting; single agent or combination; bevacizumab or no bevacizumab), patient selection (surgical outcome, biomarker eligibility, prognosis) and primary analysis population (intention-to-treat, BRCA mutated or homologous recombination deficiency positive) affect the conclusions that can be drawn from these trials. Overall survival data are pending and there is limited experience regarding long-term safety.CONCLUSIONS: PARP inhibitors play a pivotal role in the management of newly diagnosed ovarian cancer, which will affect subsequent treatment choices. Refinement of testing for patient selection and identification of regimens to treat populations that appear to benefit less from PARP inhibitors are a priority.

AB - BACKGROUND: In recurrent ovarian cancer, poly(ADP-ribose) polymerase (PARP)-inhibiting agents have transformed the treatment of platinum-sensitive disease. New data support use of PARP inhibitors earlier in the treatment algorithm.DESIGN: We review results from recent phase III trials evaluating PARP inhibitors as treatment and/or maintenance therapy for patients with newly diagnosed ovarian cancer. We discuss the efficacy and safety of these agents in the all-comer and biomarker-selected populations studied in clinical trials, and compare the strengths and limitations of the various trial designs. We also consider priorities for future research, with a particular focus on patient selection and future regimens for populations with high unmet need.RESULTS: Four phase III trials (SOLO-1, PAOLA-1/ENGOT-OV25, PRIMA/ENGOT-OV26 and VELIA/GOG-3005) demonstrated remarkable improvements in progression-free survival with PARP inhibitor therapy (olaparib, niraparib or veliparib) for newly diagnosed ovarian cancer. Differences in trial design (treatment and/or maintenance setting; single agent or combination; bevacizumab or no bevacizumab), patient selection (surgical outcome, biomarker eligibility, prognosis) and primary analysis population (intention-to-treat, BRCA mutated or homologous recombination deficiency positive) affect the conclusions that can be drawn from these trials. Overall survival data are pending and there is limited experience regarding long-term safety.CONCLUSIONS: PARP inhibitors play a pivotal role in the management of newly diagnosed ovarian cancer, which will affect subsequent treatment choices. Refinement of testing for patient selection and identification of regimens to treat populations that appear to benefit less from PARP inhibitors are a priority.

KW - niraparib

KW - olaparib

KW - ovarian cancer

KW - PARP inhibitor

KW - phase III

KW - veliparib

UR - http://www.scopus.com/inward/record.url?scp=85088781386&partnerID=8YFLogxK

U2 - 10.1016/j.annonc.2020.06.004

DO - 10.1016/j.annonc.2020.06.004

M3 - Journal article

C2 - 32569725

VL - 31

SP - 1148

EP - 1159

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 9

ER -

ID: 60987070